Understanding Anti-Nuclear Antibodies and Their Role in Autoimmune Disease Screening
Samwel Mikaye, Chief Executive Officer at Samik Medical Center, shared in the Laboratory Professionals International group on LinkedIn:
”Anti-Nuclear Antibody (ANA)
What Are They?
Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that mistakenly attack the nucleus of the body’s own cells. The nucleus contains DNA, RNA, and associated proteins, so ANA may target these nuclear components, including nucleotides.
Why Are ANA Tested?
The ANA test is mainly used to screen for autoimmune diseases, especially:
• Systemic Lupus Erythematosus (SLE) — most commonly associated
• Sjögren’s Syndrome
• Scleroderma (Systemic Sclerosis)
• Mixed Connective Tissue Disease
• Autoimmune Thyroid Disorders (sometimes)
• Rheumatoid Arthritis (occasionally)
How Is the Test Reported?
• Results are given as titers, such as 1:40, 1:160, or 1:320.
• A higher titer suggests stronger autoimmune activity.
• The pattern seen in the lab (e.g., homogeneous, speckled, nucleolar, or centromere) may help indicate which autoimmune condition is more likely — but pattern alone is not diagnostic.
Important Interpretation Notes
• A positive ANA does not always mean disease.
• Many healthy individuals, especially elderly or those with infections, may have low-level ANA positivity.
• A negative ANA makes lupus very unlikely, but does not completely rule out all autoimmune disorders.
• Additional specific antibody tests (like anti-dsDNA, anti-Smith, anti-Ro/La) are often required to confirm diagnosis.
Key Takeaways
- ANA are antibodies that react against the body’s own cell nuclei
- Used mainly as a screening tool for autoimmune diseases like lupus
- Positive ANA alone is not enough for diagnosis — symptoms and further tests are essential
- Negative ANA reduces likelihood of lupus significantly.”
Stay updated with Hemostasis Today.
-
Jul 18, 2026, 16:03Robert Tadevosyan: A Week of Science, Collaboration, and Growth at ISTH 2026
-
Jul 18, 2026, 16:02Lindsey George: Understanding the Enhanced Activity of FVIII Aurora
-
Jul 18, 2026, 15:57Ghaya Nasr: Advancing Care Standards and Therapeutic Progress at ISTH 2026
-
Jul 18, 2026, 15:49Heghine Khachatryan: ISTH 2026 – Final Day Highlights
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium